News Releases Year None202220212020201920182017 NuCana Announces Re-Opening of Global Phase III Study of Acelarin Plus Cisplatin in Patients with Biliary Tract Cancer (NuTide:121) May 05, 2020 NuCana Provides Update on Impact of COVID-19 on Clinical Studies Apr 02, 2020 NuCana Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Business Update Mar 10, 2020 NuCana Reports Preliminary Data from Phase II Study of Single-Agent Acelarin (NUC-1031) in Patients with Platinum-Resistant Ovarian Cancer Mar 10, 2020 NuCana Receives Positive Opinion for Orphan Drug Designation in the European Union for Acelarin (NUC-1031) for the Treatment of Patients with Biliary Tract Cancer Mar 04, 2020 NuCana to Present at the Cowen and Company 40th Annual Health Care Conference Feb 25, 2020 NuCana Announces First Patients Dosed in Both US and Europe in Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer Jan 27, 2020 NuCana to Participate in the Piper Jaffray 31st Annual Healthcare Conference Nov 26, 2019 NuCana to Present at the Jefferies 2019 London Healthcare Conference Nov 14, 2019 NuCana Reports Third Quarter 2019 Financial Results and Provides Business Update Nov 13, 2019 Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
NuCana Announces Re-Opening of Global Phase III Study of Acelarin Plus Cisplatin in Patients with Biliary Tract Cancer (NuTide:121) May 05, 2020
NuCana Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Business Update Mar 10, 2020
NuCana Reports Preliminary Data from Phase II Study of Single-Agent Acelarin (NUC-1031) in Patients with Platinum-Resistant Ovarian Cancer Mar 10, 2020
NuCana Receives Positive Opinion for Orphan Drug Designation in the European Union for Acelarin (NUC-1031) for the Treatment of Patients with Biliary Tract Cancer Mar 04, 2020
NuCana Announces First Patients Dosed in Both US and Europe in Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer Jan 27, 2020